Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   26 Trials   26 Trials   4609 News 


«12...7891011121314151617...5758»
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    USE OF ECULIZUMAB FOR CARDIAC DYSFUNCTION IN TYPICAL HEMOLYTIC UREMIC SYNDROME: A CASE REPORT () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_2096;    
    He continued renal replacement therapy until improvement of renal function and was discharged home without significant complications. Eculizumab could be a useful therapy for extrarenal manifestations of STEC HUS, particularly in severe cases with continued decompensation and lack of improvement with standard therapy.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
    Journal:  Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future. (Pubmed Central) -  Jan 14, 2023   
    The long-acting C5 monoclonal antibody ravulizumab is now approved for atypical hemolytic uremic syndrome treatment, enabling a reduction in the dosing frequency and improving the quality of life in patients with atypical hemolytic uremic syndrome. New strategies for additional and novel complement blockage medications in atypical hemolytic uremic syndrome are under investigation.
  • ||||||||||  NM8074 / NovelMed
    Trial completion date, Trial initiation date, Trial primary completion date:  Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris (clinicaltrials.gov) -  Jan 10, 2023   
    P2,  N=12, Not yet recruiting, 
    The benefit of eculizumab in chronic progressive C3 glomerulopathy is limited. Trial completion date: Jun 2024 --> Nov 2024 | Initiation date: Feb 2023 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Oct 2024
  • ||||||||||  Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
    SS4. Industry Supported Satellite Symposium 4: A Deeper Look at Neuromyelitis Optica Spectrum Disorder: A Glimpse Onto the Clinic Floor with Specialists (Marriott Marquis San Diego Marina) -  Jan 10, 2023 - Abstract #ACTRIMSForum2023ACTRIMS_Forum_71;    
    Target Audience The target audience for this CME initiative includes neurodegenerative disease specialists, general neurologists, advanced practice neurology professionals, and other healthcare professionals involved in the diagnosis and long-term management of patients with NMOSD. Learning Objectives Upon completion of the educational activity, participants should be able to: Compare and contrast your diagnostic and management approaches for patients with diverse presentations of NMOSD to those of specialists and affirm or modify your decision-making accordingly Distinguish key clinical and radiological features that distinguish NMOSD alongside rising tools for prognosis in order to more rapidly diagnose and tailor clinical strategies to individuals with both AQP4-IgG seropositive and seronegative presentations of the disease Assess clinical investigator perspectives on the optimal management of acute attacks, including appropriate corticosteroid and plasma exchange protocols, and subsequent follow-up in order to maximize acute recovery and formulate effective management plans long term Describe the roles of, most recent data evaluating, and clinical experience utilizing agents specifically designed to treat NMOSD to integrate them more effectively into practice and maximize patient outcomes
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    LUPUS MYOCARDITIS: A RARE CASE OF CARDIOGENIC SHOCK (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_1728;    
    She was started on cyclophosphamide and IV steroids and eculizumab after much multi-disciplinary discussion.Decision?making: Initial evaluation was focused on acute management but overall care for this patient involved a multi-disciplinary team approach. This case demonstrates that initial evaluation of cardiogenic shock in the emergency department should include differential should be broad, that a multi-disciplinary approach should be sought when delivering patient care, and that lupus myocarditis is difficult to treat.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Cosentyx (secukinumab) / Novartis, zilucoplan (RA101495) / UCB
    Review, Journal:  "New immune horizons in therapeutics and diagnostic approaches to preeclampsia". (Pubmed Central) -  Dec 25, 2022   
    Monoclonal antibody against IL-17(Secukinumab) has been proposed to alter the Th imbalance in PE...Monoclonal antibody against IL-17(Secukinumab) has been proposed to alter the Th imbalance in PE. Autologous Treg therapy and immune checkpoint inhibitors like anti-CTLA-4 are emerging as new candidates in immune horizons for PE management in the future.
  • ||||||||||  Journal:  Diagnosis and Management of Myasthenia Gravis. (Pubmed Central) -  Dec 21, 2022   
    Carefully selected treatment improves outcomes in MG. Additional treatment options for MG will likely be available in the near future.
  • ||||||||||  Tavneos (avacopan) / Kissei, Amgen, Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. (Pubmed Central) -  Dec 20, 2022   
    Thus, as therapeutic options targeting complement components are making rapid strides, the primary complement pathway involved in AAGN disease progression remains to be elucidated: this will directly impact the development of novel therapeutic strategies with high specificity and reduced side effects. This review summarizes and discusses the most recent evidence on the crucial roles of the complement system in the development of AAGN and possible therapeutic strategies that target complement components for disease management.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Soliris (eculizumab) / AstraZeneca, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Retrospective data, Journal:  COVID-19 vaccination and Atypical hemolytic uremic syndrome. (Pubmed Central) -  Dec 20, 2022   
    Here we present three patients who developed de novo or relapse atypical hemolytic uremic syndrome (aHUS) in native kidneys, a median of 3 days (range 2-15) after mRNA-based (Pfizer/BioNTech's, BNT162b2) or adenoviral (AstraZeneca, ChAdOx1 nCoV-19) COVID-19 vaccination...After eculizumab treatment, kidney function fully recovered in 2/3 patients...Still, the overall risk is limited and we clearly advise continuation of COVID-19 vaccination in patients with a previous episode of aHUS, yet conditional upon clear patient instruction on how to recognize symptoms of recurrence. At last, we suggest monitoring serum creatinine (sCr), proteinuria, MAHA parameters, and blood pressure days after vaccination.
  • ||||||||||  Empaveli (pegcetacoplan SC) / Apellis, SOBI
    Review, Journal:  Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria. (Pubmed Central) -  Dec 3, 2022   
    Long-term data would be beneficial to further support the safety profile of pegcetacoplan. Current evidence indicates that pegcetacoplan is a valuable treatment option for adults with PNH.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Thrombotic microangiopathies in surgical intensive care medicine with special consideration of atypical hemolytic uremic syndrome (Pubmed Central) -  Dec 2, 2022   
    The further differentiation of the different TMA subtypes, such as thrombotic thrombocytopenic purpura (TTP), Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS) and atypical hemolytic uremic syndrome (aHUS), based on the underlying pathophysiology and the development of new targeted treatment options in recent years have significantly improved the prognosis. A close interdisciplinary cooperation between critical care specialists and specialist disciplines experienced in the treatment of TMA, is essential for a prompt diagnosis and the initiation of the appropriate treatment.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Efficacy and Safety of Allogenic Hematopoietic Stem Cell Transplant in Paroxysmal Nocturnal Hemoglobinuria: A Single Centre Study from Pakistan () -  Nov 29, 2022 - Abstract #ASH2022ASH_7913;    
    Current indications for HSCT include a suboptimal response to eculizumab, severe AA/PNH, clonal evolution to myelodysplastic syndrome (MDS), or acute myelogenous leukemia2...Graft versus host disease (GVHD) prophylaxis was with Antithymocyte globulin (ATG) + Cyclosporin (CSA) in patients receiving NMA conditioning or ATG + CSA + short term Methotrexate (MTX) in those receiving MAC.Result s :Median age of the study cohort was 24 years (range, 18 to 42 years) and all were male...One patient (PNH/AA) had secondary graft failure on Day +46. With a median post-transplant follow-up of 15 months (range, 4 to 157) overall survival (OS) was 93.7% and disease-free survival (DFS) was 87.5%.Conclusion :In resource constrained, LMIC, where complement inhibitor therapies are currently unavailable, allogenic HSCT remains the valid option for treatment of PNH, with good overall survival rate and acceptable treatment related toxicites.
  • ||||||||||  Ultomiris IV (ravulizumab IV) / AstraZeneca
    Population Pharmacokinetic Analyses of Ravulizumab on-Body Delivery System for Subcutaneous Administration in Patients with Paroxysmal Nocturnal Hemoglobinuria () -  Nov 29, 2022 - Abstract #ASH2022ASH_7112;    
    P1, P3
    Simulations using the popPK model predicted that switching SUBQ or IV ravulizumab administration route still maintained ravulizumab concentration within the target exposure range supporting treatment flexibility for patients receiving ravulizumab, and that the studied dose regimen maintained ravulizumab concentrations above the PK threshold for patients with body weight ≥ 100 kg. This study illustrates the utility of popPK modeling and simulation to supplement clinical trial results in expanding the target population and dosing options for patients with rare diseases.
  • ||||||||||  Empaveli (pegcetacoplan SC) / Apellis, SOBI
    Impact of Pegcetacoplan on Paroxysmal Nocturnal Hemoglobinuria Symptoms in Patients Previously Treated with C5-Inhibitors () -  Nov 29, 2022 - Abstract #ASH2022ASH_7105;    
    Patient-reported symptom experience on C5-is and pegcetacoplan is summarized in Figure 2.Conclusion s This study revealed that patients continue to experience residual PNH symptoms while on C5-is and describes improvement of patients' symptom management as it relates to incidence, frequency, and severity after switching to pegcetacoplan. Characterizing the real-world experience of PNH patients on therapy is essential to optimizing treatment options and tailoring therapies to the needs of patients.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Pregnancy in Paroxysmal Nocturnal Hemoglobinuria - a Systematic Review () -  Nov 29, 2022 - Abstract #ASH2022ASH_7103;    
    There were less premature births and spontaneous miscarriages and greater fetal survival when eculizumab was given. A tendency to fewer cases of pre-eclampsia and maternal infections was also seen.